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Abstract
High vaccination rates have a social protection function in addition to individual
prevention of infections and diseases. To reach herd immunity thresholds and
to protect risk groups, the timeliness of immunization is an important goal for
vaccination policy. There is currently no causal evidence of age-appropriate im-
munization for childhood vaccinations. This research investigates how changing
the recommended timeliness of vaccination in childhood affects vaccination sta-
tus, leaving the number of doses during the primary vaccination unchanged. I
analyze an adaption in 2001 that shifts the timeliness two and a half years earlier
within the second year of life. Using representative German survey data based
on vaccination cards, I investigate a timeliness adaption of the measles primary
vaccination in 2001, which changed the scheduled age of the second dose among
young children aged 2 to 7 years, and use variation of the implementation across
states. For adjusted timeliness of the second measles vaccination, the data imply
a significant shift into earlier ages after the policy for the treatment group. In
the short run, a difference-in-difference strategy implies causal evidence of the
up-to-date vaccination probability at the end of the 7th year of life. Additionally,
the adaption induced a significant timeliness effect on the up-to-date level of the
first measles dose at the end of the second year of life. This effect can be seen as
evidence that individuals, in this case parents, respond to nonbinding vaccination
recommendation policies and that timing of vaccination is an important factor for
reaching vaccination policy aims.
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1 Introduction
“This century promises to be the century of vaccines, with the potential to erad-
icate, eliminate or control a number of serious, life-threatening or debilitating
infectious diseases, and with immunization at the core of preventive strategies.”
(Global Vaccine Action Plan, World Health Organization WHO (2013, p. 13))
For 14 out of 252 vaccine-preventable infections, the German immunization
schedule recommended a primary vaccination within the first two years of life in
2018 (see STIKO (2018, p. 338)). Vaccination is a highly effective way that par-
ents can protect their children from more than a dozen major infectious diseases,
sequelae, hospitalization and even death3: looking at the measles vaccine, the
field effectiveness of the first dose is on average 91 % regardless of a child’s age
or region. Studies for Europe showed an effectiveness between 79 and 99 % for
the first dose and between 93 and 99 % for the second dose.4 From 2000 to 2015,
measles incidence rates declined by 75 %.
Although there is an effective vaccine, there were still 36 cases per million
population contracted worldwide in 2015, the majority among children under the
age of 5.5 Based on this information, the measles death rate was estimated at
134,200 worldwide (see Patel et al. (2016, p. 1230f)). Additionally, there are
risks for secondary diseases such as ear infections, bronchitis, and pneumonia as
well as long-run risks such as brain inflammation of the type subacute sclerosing
panencephalitis (called SSPE) (see Moss and Polack (2001, p. 298), McLean et al.
(2013, p. 3) and Scho¨nberger et al. (2013)). The virus still ranks first in the list of
deaths for vaccine-preventable diseases worldwide6; therefore, a continuing priority
2Number of infections with existing licensed vaccines (see WHO (2013, p. 16)).
3For a short historical summary for the United States of America, McLean et al. (2013)
described incidence, hospitalization and death rates for measles, rubella, and mumps.
4See Uzicanin and Zimmerman (2011) for a review of the field effectiveness for measles.
5For Germany, children under 5 years had highest incidence rates in 2001 (30 %) and 2017
(over 35 %) (Hellenbrand et al. (2003, p. S213) and Matysiak-Klose and Wicker (2017, p. 1769)).
6In 2000, measles caused 5 % of all child deaths under the age of 5 and were responsible for
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of measles eradication has been pursued for decades (see Kabra and Lodha (2013,
p. 2)). For both Germany and the European WHO region, this goal7 should have
already been reached in 2010, but it was postponed several times and is currently
set for 2020 (see Federal Ministry of Health (2015)).
Why is it so difficult to eradicate the measles despite its high vaccine effective-
ness?
The measles virus is highly contagious on contact (e.g., air, droplet, or casual
touching). Symptoms initially resemble a cold or flu until a typical skin rash ap-
pears. However, individuals are already infectious and transmit the virus before
a skin rash outbreak (see Halloran, Longini Jr., and Struchiner (2010, pp. 11,
64, 220)). In addition to the aggressive nature of measles, challenges are driven
by a shortened protection period after birth by maternal antibodies within the
first year of life and the waning of vaccine-induced immunity8, as well as vaccine
fatigue9. Factors for fatigue are seen in the individual perception of incidence
and secondary diseases10, persisting misinformation and beliefs (e.g., fraudulent
evidence regarding autism in the late 1990s), or medical, religious and philosoph-
ical exemptions (see Salmon et al. (1999)). All these factors increase contagion
potential over the lifecycle.
To facilitate a successful implementation of the WHO strategic plan for the
eradication of measles, a high overall nationwide vaccination coverage (over 95 %)
with two doses of measles vaccine11 should be achieved. Additionally, susceptible
subgroups of people must be identified and targeted by vaccination programs
in order to interrupt the transmission of measles (see WHO (2005 and 2013),
Halloran, Longini Jr., and Struchiner (2010, p. 59)).
over 40 % of all deaths of vaccine-preventable infections for children under the age of 15 (see
WHO (2002, p. 50)).
7Eradication of measles in the European region is defined by an immunization coverage over
95 %, an incidence under 1 per million population per region and year, and no deaths (see
Ramsay (1999, pp. 1, 13)).
8In the past, the term of protection for newborns was longer because the mothers them-
selves had experienced measles. For vaccinated mothers, the protective function of the child is
shortened (see Waaijenborg et al. (2013)). Similarly, a decrease in vaccine-induced immunity
is anticipated, as the mechanism of lifelong immunity has yet not been fully understood (see
Halloran, Longini Jr., and Struchiner (2010, p. 59) and Moss and Polack (2001, p. 302).
9This can be observed in all vaccine-preventable diseases and is not a specific measles problem
(see Larson et al. (2011)).
10Local and/or regional success contrarily causes less perception of disease risk and risks of
secondary diseases (see (Matysiak-Klose and Wicker (2017, p. 1767)).
11With an average vaccine effectiveness of 91 %, even if all received one dose, the necessary
threshold would not be reached.
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However, which policy should the government implement to achieve its goals?
There is considerable heterogeneity: policy options (e.g., mandates, recom-
mendations, or mixed policies) are combined with vaccination programs, cultural
or national features, legal frameworks, ethical justifications, and access to vacci-
nations. However, evidence is rare, and external validation is difficult.12
Empirical evidence for the causal effects of vaccination policies had only been
established for certain select vaccinations. The empirical strategy is to use a nat-
ural experiment that randomly assigns the vaccination policy to the population.
State-level introduction over time represents a suitable exogenous variation using
a treatment-control group design to investigate national evidence.
To the best of my knowledge, Abrevaya and Mulligan (2011) and Lawler (2017)
investigate U.S. vaccination policies in the last two decades in such a causal
manner. Abrevaya and Mulligan (2011) show that vaccination rates for vari-
cella (chicken pox) increased after introducing state-level mandates in 2000. For
hepatitis A, Lawler (2017) finds evidence for two policies - recommendations and
mandates - enacted in 1999 or later at the state level. Both policies significantly in-
creased vaccination rates and are associated with decreasing incidence. Given the
few studies examining the causal effect of the introduction of childhood vaccination
policies, such as mandates or recommendations, on immunization rates exploit-
ing state-level diversity, there is no causal evidence of the timeliness of childhood
vaccinations. For European countries and the Commonwealth of Independent
States, investigations of measles/measles-mumps-rubella (MMR) timeliness have
been limited to cross-sectional and survival analyses without control groups: e.g.,
for Germany (Fell, David, and Reintjes (2005) and Siedler et al. (2002)), for Swe-
den (Dannetun et al. (2004)), for the UK (Walton et al. (2017)), and for Armenia,
Kazakhstan, Kyrgyzstan and Uzbekistan (Akmatov et al. (2008)). The same ap-
plies to Canada (Pe´rinet et al. (2018)).
Despite the importance of timely immunization, there has been extremely
limited empirical research focusing on the effects of an age-appropriate implemen-
tation of vaccination policies.
On the one hand, to estimate the causal effect of an age-appropriate vacci-
nation policy we have to exploit exogenous variation and random assignment of
age-specific recommendations. Since reunification, the German vaccination pol-
icy has undergone a number of changes, e.g., nationwide introduction of new
12See MacDonald et al. (2018), which described factors that should be mentioned together
with an implementation strategy such as mandates but that also apply to other policy strategies.
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vaccination (for instance, haemophilus influenzae type b) or a change in timing
recommendations by several months. The reform that I seek to exploit is the
adaption of the second measles dose from the fifth to second year of life in 2001.
In this context, an exogenous source would be diverse responses within the public
vaccination guidance of individual federal states because implementation of the
vaccination recommendations is the responsibility of the federal states. The rec-
ommendation of the second measles dose of the primary immunization and its
timeliness adaption by several years is one such unique case within the German
vaccination system.
On the other hand, the main problem has been the availability of national
vaccination records (see Fell, David, and Reintjes (2005, p. 29) for the German
case). With the “The German Interview and Examination Survey for Children
and Adolescents (KiGGS)” from the Robert Koch Institute (RKI), such data are
now available. One limitation of the KIGGS data is that the data allow us to
analyze the effect of the 2001 timeliness adaption for measles only in the short
term since birth cohorts up to and including 2003 could be considered to end
4 years after the policy. Additionally, information about the vaccination status
and timing for both measles doses are not exactly known: the measles status
for the first dose at the age of 2 years and for the second dose at the age of 7
years. Since a pure recommendation policy without binding age limits is applied
within this analysis, the latter point seems less critical because a certain delay in
measurement does not appear problematic.
My paper contributes to the previous literature in several ways. First, I provide
evidence for the effect of an age-appropriate recommendation policy, here the
recommended timing of the second measles dose. The up-to-date measles status at
the interview period between 2003 and 2005 allows me to analyze the age-specific
vaccination shift of the recommendation adaption in a control group setting.
Second, using the state-level variation of the adaption of the age-appropriate
timing in 2001 and the age-specific information about the up-to-date status at
the age of 7 years before and after policy change, I estimate the causal adaption
effect of the recommendation on the vaccination probability for the timely second
measles dose and fill the lack of timeliness evidence in the vaccination context.
Third, in addition to the direct policy effect on the measles status of the second
dose, I investigate the ‘side effects’ of the adaption on the first measles vaccination
demand. Due to the shift into the second year of life temporally following the first
vaccination in the context of the primary immunization, it is to be assumed that
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the 2001 adaption also affects the first dose status at the age of 2 years.
Fourth, these analyses will be extended with a regional stratification, a dy-
namic policy regression model for short-term dynamics, and a robustness section
in which methodological and content-related aspects are additionally discussed.
Finally, the effect of the adaption on measles incidence rates in Germany is
considered with reporting data and will be discussed.
Results at a glance: An up-to-date analysis shows a clear increasing trend
from 2003 to 2005 over all ages from 2 to 6 years with constant rates within the
control group at the same time. For the difference-in-differences (DD) framework,
the common trend assumption holds and individuals who are affected by the
adaption already respond in the short run. For both the first and second measles
dose, there is a significant positive effect of over 9 percentage points.
The regional stratification differs for the second measles dose but is equal for
the first dose. The dynamic policy results give a constant probability effect for
the first dose and some increasing effect for the second dose.
The remainder of the paper proceeds as follows. In Section 2, economic theory
on vaccination is considered. Section 3 summarizes the historical and institu-
tional background and measles vaccination policy for the German case. Section
4 describes the data source and the variables used. Section 5 presents the empir-
ical strategy. The main results are presented in Section 6. Section 7 gives some
robustness analyses. Finally, Section 9 concludes with a discussion of the main
findings.
2 An economic view on vaccination decisions and
policies
From a theoretical point of view, there is no clear statement about the effect or
direction of individual vaccination decisions. The commodity ‘protected against
preventable infections’ by vaccinations suffers from free-riding and external effects,
decisions under uncertainty and misinformation13.
At the individual level, there is a decision trade-off between costs (in particular,
13There are other predictors that have also been named and recognized in the literature. From
a medical point of view, missed appointments or the impossibility of vaccination due to acute
illness and social neglect play a major role (see Schmitt (2001, S3)). Poethko-Mu¨ller, Kuhnert,
and Schlaud (2007) and Poethko-Mu¨ller et al. (2009) analyze sociodemographic predictors, such
as socioeconomic status (outcome and proxy of preferences) or migration status, and parental
factors, such as beliefs, in Germany.
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time and suffering from side effects) and benefits (individual protection). Addi-
tionally, society gains from decreasing transmission of diseases, which depends on
the proportion of people being vaccinated in society (social protection): individual
protection reduces the likelihood of infection of all unvaccinated persons and the
population prevalence decreases (physical positive externality). Therefore, high
vaccination rates give an incentive for non-vaccination because the individual prof-
its from the transmission reduction and could avoid vaccination costs. Due to this
externality, socially optimal demand is not reached (see Zweifel, Breyer, and Kif-
mann (2009, p. 157f)). Both situations lead to an inefficient (too low) vaccination
rate, since the individual does not take into account the positive external effect
and tends to free-ride.14
In addition, Geoffard and Philipson (1997) showed that the demand for vac-
cines are prevalence dependent - with an increase population vaccination rate and
the willingness to pay for immunization decreases. that prohibits the eradication
totally of such infections.
Additionally, the vaccination decision is a decision under uncertainty: pay the
costs today and receive the benefits (perhaps) tomorrow. Therefore, risk and time
preference also play an important role in the health context and for vaccination
decisions. The role of economic and other preferences in the individual vaccination
context has been analyzed empirically with survey data (see, e.g., Nuscheler and
Roeder (2016)) or within laboratory experiments (see, e.g., Binder and Nuscheler
(2017)).
Misinformation and misperception relate, for example, to the effectiveness of
vaccination and the assessment of the likelihood of infection in the context of vac-
cination.15 Research had already shown that people generally and in the health
context have problems with misleading beliefs and correct perception (e.g., op-
timistic bias) (see Weinstein (1982 and 1987), e.g., in the context of smoking
behavior see Viscusi and Hakes (2008)). Many investigations have supported
these points for individual vaccination decisions: For both patients and doctors,
inadequate information and misjudgments about vaccinations and vaccines are im-
portant issues (see Favin et al. (2012), Nuscheler and Roeder (2016), and Smith
et al. (2017)).
14There is empirical research that analyzes these points, e.g., Ibuka et al. (2014) observed
free-riding under laboratory conditions or the quantity of external effects by Boulier, Datta, and
Goldfarb (2007).
15Nuscheler and Roeder (2012) found a huge impact of misinformation next to the role of
family doctors for the influenza vaccination with German survey data.
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This consideration raises the social and political question of which vaccination
policy and incentives can be pursued to support the individual vaccination decision
and reach the social goals (e.g., herd immunity, disease eradication).
The effectiveness of the measles vaccination is high, but not perfect (see 1).
Looking at monetary incentives, Rosian-Schikuta et al. (2007) give an interna-
tional review of costs and benefits for the MMR vaccination; for Germany, data
are not available. Generally, the costs of the disease and estimated indices (such
as cost-benefits) vary widely across countries and subgroups, but from a mone-
tary point of view, vaccinations are preferable to the disease infection and treat-
ment costs. The subsidization of costs by public health or health insurance is
widespread. In Germany, the vaccine and the medical expenses of recommended
vaccinations are covered by health insurance.
One might argue that because of the mentioned market failures, only vacci-
nation mandates can achieve immunity and eradication goals, and they are the
preferred choice instead of a recommendation policy. Geoffard and Philipson
(1997) showed theoretically that even vaccination mandates could not reach dis-
ease eradication because of the nature of vaccination demand.16 In addition to
financial and market arguments, the enforcement of a vaccination policy depends
on the country in view of the legal framework and historical conditions.
3 Institutional background
Historically, before the German reunification in 1990, the German Democratic
Republic (DDR) instituted vaccination mandates for children and adults. In the
Federal Republic of Germany (FRG), there was only one general vaccination man-
date: the pox vaccination between 1945 to 1983. After abolishment until today,
health authorities pursued a simple nonbinding recommendation policy for citi-
zens in contrast to other industrial countries, such the U.S. and other European
countries.
3.1 Structural organization
In Germany, the Paul-Ehrlich Institute (PEI) is the agency responsible for evalu-
ating the safety and efficacy of new vaccines. The Standing Committee on Vacci-
16See Brito, Sheshinski, and Intriligator (1991) for further theoretical investigations about
the justification of mandates and comparison to other regimes such as free choice.
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nation17 (STIKO) at the RKI18 develops annual evidence-based national recom-
mendations for the use of licensed vaccines by the PEI. These recommendations
are age- and subgroup-specific, but they are not legally binding at the state level.
By law, each federal state has to extend its public vaccination guidance based
on the STIKO recommendations. Following the approval of a new vaccination or
timeliness recommendations, individual states may conform with it or differ from
it.19 Participation in the program is voluntary, and the STIKO recommended vac-
cination are nowadays offered free of charge by sickness funds.20 The majority of
all vaccinations in childhood take place in the outpatient sector by pediatricians
and family physicians.
3.2 Measles recommendations, status and research ques-
tions
In Germany, the measles vaccination has been recommended by the STIKO since
1974 (see STIKO (1974, p. 291)). Starting with a monovalent21 live vaccine for
measles, there is a trivalent MMR vaccine that has been licensed and recommended
by the STIKO for West Germany since 1988 (see STIKO (1988, p. 412)). During
the division of Germany, the measles vaccination was mandated for all children at
9 months in the DDR and was recommended at 12 months in the FRG; after 1980,
it was recommended at 14 months (see STIKO (1980, p. 314)). After reunification,
the FRG recommendations were adopted. Since that time, there was one adaption
of the first measles dose: In 1997, the timing of the first dose was dated between
11 and 1422 months of life (see STIKO (1997, p. 101)).
In 1991, the STIKO recommendation for a second measles dose23 was published
17The committee is a national immunization technical advisory group appointed by German
Federal Ministry of Health. For detailed information on structure, working procedure and
publications, see STIKO (2016).
18The RKI emerged from the Federal Health Agency (“Bundesgesundheitsamt”), which was
dissolved in 1994.
19The separation of national and federal state levels is based mostly on monitoring, claim for
damages of injuries from immunization (see §11 and §60 Infektionsschutzgesetz (IfSG))
20After the annual publication by the STIKO within a time span of a few months, the Federal
Joint Committee decide to cover the payment for vaccination of the immunization schedule by
the service catalog of the statutory health insurance.
21One licensed single measles vaccine is still listed in Germany (compared to 21 tri/tetravalent
vaccines) (licensed vaccine list available under www.pei.de/impfstoffe)
22If admission to a childcare institution is considered, the MMR-series could start at 9 months.
Then, a second dose is recommended at 14 months (see STIKO (1995, p. 109)).
23In the DDR, a second measles dose was mandated, and after reunification, was recom-
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for all children aged 5 years and older and was adopted by all federal states (see
STIKO (1991, p. 384)). This recommendation was motivated by evidence from
the U.S. and some Scandinavian countries to improve the lack of immunity and
to obtain adequate herd immunity on a population level.
For practical reasons, the school entry health exam24 is mentioned as a good
point in time for the second measles dose indication (see STIKO (1995, p. 109f)).
Since 1998, the recommended age in the STIKO immunization schedules was cited
at age 4 and older (see, e.g., STIKO (1998, p. 104)) without any explanation or
text mention. However, the controlling advice within the school entry health exam
persisted in all STIKO recommendation publications until the 2001 recommenda-
tion adaption.
In 2001, the STIKO timing of the second dose was shifted to within the sec-
ond year of life (15 to 23 months of age) in connection to the first dose (see
STIKO (2001, p. 205)). The dating of the second dose into the second year of
life was justified with the importance of an early and timely immunization and
initial vaccinations without sufficient immune response (nonresponders) should be
compensated as early as possible. Because in the first two years of life additional
vaccinations and well-child visits are pending, there are comparatively more doctor
contacts. The temporal coincidence supports the vaccination implementation.25.
Fifteen federal states instituted the new timing of the second measles dose, but
only the Free State of Saxony maintained its timing at 5 years and above until
2016.26 The population living in the Free State of Saxony will be the control group
in the data used for the policy evaluation of families that live in the treatment
mended for one year without the STIKO recommendation.
24This screening takes place nationwide and is obligatory for all preschool children. It is
organized in the preschool year by the local Department of Health. In general, children are
required to attend school if they have their 6th birthday before the deadline (country-specific
between June and September) and will be enrolled at the earliest possible date. This data source
is still used widely for official publications on the vaccination status of children and adolescents
at school enrollment.
25In phases of recommended well-child visits within fixed-time windows, vaccination coverage
increases (see figure 2 in Rieck et al. (2013, p. 3))
26Both the STIKO and the Free State of Saxony rely on evidence from the U.S. and other
industrial countries for their timing recommendation. For example, in the U.S. the Center
for Disease Control and Prevention and the Advisory Committee on Immunization Practices
recommend a 2-dose series at 12–15 months and 4–6 years. The WHO recommended the second
measles vaccination at school entry conditional on high vaccination rates for the first dose (> 90)
and high school enrollment (> 95), and otherwise in the second year of life (see WHO (2017,
p. 221)). Since 2017, the second measles recommendation in the Free State of Saxony has been
at 45 months of age and older (Sa¨chsiche Landesa¨rztekammer (2018)). Nevertheless, the second
dose is preferable for indication (e.g., measles exposure; note that the minimum length of time
to the first vaccination is 3 months).
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states. This STIKO timeliness adaption was the first adaption of more than 2
years of an existing recommendation, which means that the possible time span of
a timely immunization is more than halved.
Since 2006, the varicella (‘chicken pox’) vaccination has been recommended
and could be combined with MMR (e.g., with a licensed tetravalent vaccine) (see
STIKO (2006).)
An overview of the age-specific recommendations for the measles27 vaccination
since introduction of the second dose until today is listed in Table 2.1.
Table 2.1: STIKO measles recommendation for primary vaccination
Measle Recommendations and time span 1991–2019
dose 8/19911–2/1997 3/19971–2/1998 3/19981–6/2001 7/20011–2019
1st 14 11–14 11–14 11–14
2nd 60 60 (48–) 60 15–23
Notes: The age limit (in months) represents the recommended age that
a child should be (at a given point in time) and be eligible for the
first/ second measles dose. 1 Publication date of the vaccination rec-
ommendations. Sources: STIKO (1991, 1997, 1998, 2001, and 2018).
Since 2001, the states have reported infections and vaccination status in school
entry health exams.28
In 2016, the average German vaccination rates based on vaccination card in-
formation29 are 97.1 % for one measles dose and 92.9 % for two doses at the age
before school entry: The first rate reaches on average the critical herd immunity
threshold of 95 %, and the second is just below. The regional variation varies
for one shot from 95.2 % (Baden-Wu¨rttemberg) to 98.3 % (Mecklenburg-West
Pomerania and Saxony-Anhalt) and for two shots from 89.5 % (Baden-Wu¨rttem-
berg) to 95.8 % (Mecklenburg-West Pomerania). This was the first year that all
27In the time span from 1991 until 2018, the first and second dose recommendations against
measles, mumps and rubella are identical. Only for girls, a third rubella dose is recommended
at age 11 and older.
28The law aimed to build up a nationwide, statutory reporting and central surveillance for
all 431 county and 16 state health departments managed by the RKI (see §34 Abs. II IfSG).
Before the law, there was voluntary, nonsystematic reporting to the RKI, and rates often were
estimations on single survey data.
29Rates are based on children with vaccination cards at the health check-up before school
entry (on average between 90.9 and 92.6 % for the period 2005 to 2016; in east states, the annual
card rates are some higher, between 0.1 and 2.8 percentage points; the east-west population ratio
is approximately 1:8.)
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states exceeded the herd immunity threshold (HIT) at 95 % vaccination coverage
at least for the first dose (see Robert Koch Institute (2018, p. 153)).30
Figure 1: Measles status at school entry health exam by region
40
50
60
70
80
90
100
 
20
05
20
07
20
09
20
11
20
13
20
15
 
1st m.d.
 
 
 
 
 
 
 
 
20
05
20
07
20
09
20
11
20
13
20
15
 
HIT
All states
East
West
2nd m.d.
V
ac
c.
 c
ov
er
ag
e 
(in
 %
)
Year
Notes: Data from Robert Koch Institute (2008-2018), own calculations.
The red line is the herd immunity threshold at 0.95.
In Figure 1 looking at the data from the school entry health exam in the period
from 2005 to 2016, a continuous increase in West Germany can be seen for the
first vaccination. As of 2008, the 95% threshold was exceeded in East and West
Germany. For the second vaccination, the increase is very clear in the years 2005
to 2009, possibly due to the adjustment in 2001. Since then, the rates show a
horizontal course.
To obtain a more accurate picture at the timing of vaccination, the measles
quota by birth cohorts totally and by age of vaccination are given in Figure 2. The
data are based on the KiGGS data. On the left side, the totally up-to-date status
(solid) and the timely status at the age of 2 (dashed) for the first measles dose are
shown; shown in the right figure are the corresponding rates for the second dose
30It should be remembered, however, that for more than 7 % of the preschool child population,
the information was not documented, and the measles field effectiveness is below 100 % (see
section ??).
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totally and at the age of 7. At the beginning of the period considered, the gap
between the overall rate and the age-recommended rate for both vaccinations was
over 20 percentage points, showing a clear rapprochement over time. Interestingly,
these data for the first vaccination show a steady decline for the birth cohort in
1997 and younger. This observation shows that some of the overall rates are
achieved much later than recommended. Vaccine fatigue could of course also be
behind this finding.
Given the recommendation adaption in 2001, there are direct and indirect
investigations of interest: Directly, the adaption aims to reach an earlier date of
the second measles dose and to increase overall vaccination status at school entry.
Indirectly, the new recommended time span for the primary measles immunization
ending at the age of 2 could support a timely first immunization.
Whether and how strongly vaccination policies work is ultimately an empirical
question. This applies to mandates, recommendations and adjustments of these
policies. In summary, I investigate whether the recommendation adaption affects
the measles vaccination status
(i) for the second dose at age 2 to 6 (age shift effect)
(ii) for the second dose at age 7 (direct adaption effect) and
(iii) for the first dose at age 2 (indirect adaption effect).
Finally, I take a closer look at reporting data on the incidence of measles,
which must be legally recorded and reported by the health authorities in the
federal states since 2001.
4 Data
Initially, I will describe the dataset generally and the sample selection. Next, I
will go into more detail about the variables used in the empirical analyses, first
and foremost the individual information for the measles vaccination. After sample
stratification by birth cohorts, I will describe the covariates.
4.1 Survey data and sample selection
The KiGGS data from the RKI are a cross-sectional dataset collected between
May 2003 and May 2006. The dataset is representative of the German population
aged up to 18 and contains a massive set of sociodemographic individual and
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Figure 2: Measles status and timeliness by birth cohort
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Source: KiGGS data, own calculations.
household variables, health inputs and outcomes and information on vaccinations
based on vaccination cards records. The KIGGS data cover birth cohorts from
1985 to 2006. In a first step, 167 sample locations were randomly selected at the
community level (primary sample units). Then, age-specific random samples were
drawn from population registries (secondary sample units).31
For the analyses, the survey years 2003 to 2005 are considered because there
are no observations in 2006 for the control group. All children are mentioned that
had a vaccination card, were born and have lived since birth in Germany, and
reside with at least one biological parent. All child and household information is
provided by at least one biological parent, and observations with missing values
are dropped. The full sample has 6,272 observations. Table 2.2 shows the sample
size after the selection criteria in the upper panel. The size of the samples depends
on selected birth cohorts based on the research question and empirical analyses
(see Section 4.2).
31For more details on the setting and the sampling procedure, see Kurth (2007).
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Table 2.2: Sample selection and size
Selection criterion Sample size
None (full sample) 17,640
Survey years 2003 to 2005 14,988
birth cohorts 1993 to 2004 9,718
Child with vaccination card 9,265
Child born in Germany 8,988
Child lived with at least one biological parent 8,916
Questionnaire responder was biological parent 8,896
Observations without missing information 6,272
4.2 Vaccination status and timeliness
When analyzing the timeliness of vaccination, it is important to know the age of
the child at the time of vaccination. The most direct method of assessing the age
shift of recommendation on timely up-to-date vaccination status is to compare the
the age at vaccination before and after the adaption.32 The KIGGS data provide
such information with limitations. Retrospectively, especially for the pre-policy
period, the age-specific timeliness information on a child’s vaccination status is not
known exactly. For each individual, there is age-specific timeliness information
if the child received the first (second) measles dose before the age of 2 (7) years.
Additionally, the up-to-date information about the total sum of measles doses at
the date of interview is known.
I use two samples to analyze the recommendation adaption: the timely up-to-
date sample and the pre-post sample.
The up-to-date sample involves the post-policy period from 2003 to 2005 to
investigate the age- and group-specific up-to-date measles status of children aged
2 to 6 years for two measles doses. I also check the difference of children aged 1
to 2 years between treatment and control group for the first measles dose. The
corresponding cohorts are listed in Table 2.3.
The pre-post sample contains all children aged 2 and older for the first measles
dose or aged 7 years and older for the second measles dose before and after the
recommendation adaption. For the pre-policy period, all children were taken
into account, so the recommended vaccination age and the measured time of
vaccination status are not affected by the adaption. This is also the case for the
32For the considered time period the registry of reported data by the German health depart-
ments are not helpful for Germany because it started nationwide by law in 2001. Administrative
data derived from health insurance claims could be an alternative source if the control group is
well represented.
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post-policy period if both recommendation and measurement of the vaccination
come after the policy introduction. For earlier policy decisions or other adaption
to have no effect, I start with the previous period in 1998. Children born between
in 1999 and 2000 (first dose) and in 1995 (second dose) were excluded because the
(age-appropriate) vaccination recommendation or the school entry health exam is
before the 2001 adaption, but the measurement of vaccination status falls into the
post-period. Therefore, it is unclear whether the decision is driven by the 2001
adaption. In Table 2.3, birth cohorts considered in the analyses are defined by
sample, measles doses, age, pre-period, and post-period.
Table 2.3: Sample birth cohorts
Measles Age Vacc. age Pre-period Post-period
Sample dose (in years) (in years) 1998 – 2000 2003 – 2005 N
Up-to-
date
1st dose
1 2002 – 2004
625
2 2001 – 2003
2nd dose
2 2001 – 2003
3,114
3 2000 – 2002
4 1999 – 2001
5 1998 – 2000
6 1997 – 1999
Pre-post
policy
1st dose < 2 1996 – 1998 2001 – 2003 3,098
2nd dose < 7 1993 – 1994 1996 – 1998 2,473
4.3 Parental, household and offspring characteristics
The dataset used includes a wide range of individual and household charac-
teristics to account for individually heterogeneity. These include proxies for a
parent’s socioeconomic status (education, occupation, income), migration back-
ground, household size, birth order, and regional structure.
There is also information on child care and school enrollment. Both are criteria
that can play a role in the vaccination decision (see Section 3.2 and footnote
22). Furthermore, vaccination-specific and health-specific information is available
in the dataset, including well-child visits, medical vaccination advice, parental
reasons against vaccinations, chronic illnesses and timeliness of other vaccinations.
The vaccination guidelines advise a steady control of the vaccination status of
children as part of the well-child visits (so-called U-exams): For analyses of the first
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measles dose, the U6 (10 to 12 months old) and U7 (21 to 24 months) groups are
included; for the second dose, the U8 (46 to 48 months) and U9 (60 to 64 months)
groups are also included. In addition, medical advice and recommendation has an
important role for the parental decision, for which, of course, individual reasons
also play a role, e.g., the individual opinion of the non-need for immunization. A
child’s health can also influence the decision. There is information about a set
of chronic diseases and their first appearance by age: For the first measles dose,
all chronic diseases that occurred in the first two years of life are considered, and
for the second dose, the first three years are considered. Last but not least, it is
possible to check for the revealed vaccination preferences of the parents. Therefore,
a vaccination is considered that had taken place earlier: For the first measles dose,
the timely primary immunization for hepatitis B33 is used; the second dose is the
timely first vaccination against measles. Table 2.13 in the Appendix lists all
mentioned variables with attributes. The descriptive statistics for the full sample
and both the treatment and control groups are provided in Tables 2.14, 2.15 and
2.16 in the Appendix.
5 Empirical strategy
My empirical exploration has two parts. First, investigating the age-specific de-
velopment of timeliness, I compare the treatment and control groups (difference in
mean) in an age-period regression framework after 2001 using sample 1. Second,
I use a difference-in-differences (DD) regression framework that allows me to take
advantage of the variation in the implementation of recommendation adaption
between states using multilevel data. I estimate the policy effects of the STIKO
recommendation adaption on the parental decision of a child’s measles vaccina-
tion as an outcome variable using individual data from the KIGGS dataset. Using
sample 2, I estimate the causal effect of the recommendation adaption in 2001 for
the measles vaccinations level for the first dose at the end of the second year of
life and the second dose at the end of the 7th year of life.
To take advantage of the available observed sociodemographic information at
the individual and household level, the unit of analysis is an individual i to control
for heterogeneity and improve the power of the estimates.
After model descriptions, I will discuss the identification strategy and chal-
33I chose hepatitis B because it is still not a standard vaccination in the first year series such
as diphtheria, tetanus, or pertussis.
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lenges with serial correlation and clustering within policy evaluation.
5.1 Age shift regression model
The adaption contains a recommendation age shift into the second year of life.
Analyzing this shift effect, I use a 3-way interactions regression model for the
group-specific age-period vaccination timing. Formally, the outcome indicator for
the parental choice of child i living in state s in period t to be vaccinated against
measles is V ACist.
Pr(V ACist = 1|.) = F (agei x treateds x periodt, Xist) (1)
where Xist captures individual and household controls and treateds is the
indicator for the treatment, the age-adaption for the second measles vaccination
within the second year of life. For flexible model specification I include indicators
for age and period. For the distribution function F , the identity is assumed to be
a linear probability model (LPM). For robustness, I will estimate the regressions
with age to be continuous and squared assuming a positive increasing age-effect
on vaccination probability within the age span from 2 to 6. Additionally, I assume
the normal distribution for the distribution function to estimate a nonlinear probit
model accounting for the binary nature of the dependent variable. I will provide
graphical analyses of the partial effects because, even in linear models, these
effects require computation of the coefficients.34 In this model, the age-period
effects are of interest. I control for birth cohorts without additional restrictions
using individual records because there is no exact linear dependency between age,
period and cohort in the data (see Robertson and Boyle (1986, p. 530)): e.g.,
individuals who are 2 years old at the date of interview in the survey year 2003
might be born in the year 2000 or 2001, in the survey year 2004 in 2001 or 2002,
and so on.
34For comparison with the nonlinear model, it is also easier and more meaningful (Ai and
Norton (2003) and Greene (2010)).
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5.2 Policy evaluation regression model
Now, let V ACisτ be the outcome indicator for the parental choice of individual i
living in state s born in year τ 35 to be vaccinated against measles.
The linear probability model within the DD framework then is
Pr(V ACisτ = 1|.) = γs + λτ + βDsτ +Xisτδ + isτ (2)
where γs and λτ are state and cohort fixed effects. Individual and household
controls are captured by Xisτ . 
v
isτ is the error term. γs captures group differences
between treatment and control group before the policy change (with the assump-
tion to be constant over time in the absence of treatment), and λτ implies the
cohort effects of vaccination rates for both groups. Dsτ is an indicator whether
state s recommended the adaption for birth cohort τ and the DD estimator for
Dsτ is the parameter of interest.
36
To obtain some dynamic policy insights, the DD model can be extended to
birth cohort treatment effects:
Pr(V ACisτ = 1|.) = γs + λτ +
∑
j∈J
βj D
j
sτ +Xisτδ + isτ (3)
where γs and λτ capture state and year of birth fixed effects. D
j
sτ is an indicator
equal to 1 if cohort j, with J = {−m, ..,−1, 1, .., n}, was affected by the policy
ending with m ‘leads’ and n ‘lags’ treatment effects. The reference group will be
the last pretreatment birth cohort (j=0). The coefficients βj represent the cohort
j-specific DD estimator. Assumptions and challenges of the DD framework are
discussed in detail in the next section.
5.3 Identification and inference
I use variation across birth cohorts and state-specific age recommendations for
vaccination to identify the effect of the vaccination timeliness adaption at the
state level on individual vaccination probability. Next, to control for observed
heterogeneity by adding powerful individual controls for the vaccination decisions,
35In this model, birth cohorts are the ‘time’ perspective (see Section 4.2).
36For robustness, a nonlinear DD model is estimated (Puhani (2012)).
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both the variance of residuals and the standard errors of the estimates are reduced,
and the estimates become more precise. This approach is helpful in the DD
framework if the covariates are not affected by the timeliness adaption themselves;
otherwise, they are bad controls in the sense of Angrist and Pischke (2009, 22f,
64). The use of a timely first measles dose as a control variable in the regression
of the second dose probability is unproblematic here since the first decision was
completed prior to the policy for all birth cohorts used.
In standard difference-in-differences models, identification relies on the com-
mon trend assumption that in the absence of the policy, outcomes in the treated
states would have evolved as in the control group. More precisely, to achieve
identification, I assume linearity, and any unobserved time-varying state char-
acteristics that affect outcomes are uncorrelated with treatment. Checking this
trend assumption, I need at least two periods before the recommendation adap-
tion for both groups, i.e., treatment and control groups. With equation 3, the
significance of all leads37 of the DD estimator checks the common trend assump-
tion and should be zero (Granger causality test, see Angrist and Pischke (2009,
p. 177)).
Another point is the individual home decision. The federal state where the
family lives is a decision variable that is (at least partly) under individual control.
In response to the state’s policy decisions, parents might move. In my context, it is
unlikely that a nonbinding vaccination recommendation and its adaption directly
influence parental home decisions; both measles doses were already introduced and
are free of charge as they are statutory health insurance benefits. Therefore, it can
be assumed that when parents insist on a second vaccination, they could also go
to another state to obtain the vaccination. In the case of measles exposure, even
in Saxony, an earlier second vaccination was recommended. In addition, I cannot
control for German internal migration since the place of residence is known only at
the time of the interview and not at the time of vaccination. Public statistics show
that the majority of German internal migration takes place within a federal state,
which is not a problem in this framework of policy analyses. In addition, migration
within the states of the treatment group would not be a problem either.38.
For valid inference of the t-statistics in my regression frameworks, two pitfalls
must be considered: clustering and serial correlation (see Bertrand, Duflo, and
37Here, leads are birth cohorts that are not affected by the recommendation adaption.
38Since reunification, annual German internal migration has been approximately 5 %, of
which 34 takes place within the federal states (Destatis (2016, pp. 14, 20)).
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Mullainathan (2004) or Angrist and Pischke (2009, chapter 8)).
One challenge is the calculation of the ‘correct’ standard errors choosing the
‘right’ clusters39: The level of clustering is the highest level of aggregation deter-
mined by the data used40 or the empirical strategy. Within the DD framework,
the timeliness adaption policy affects both states and birth cohorts and must be
used as the level of clustering. This consideration accounts for the presence of a
common random effect at the state and birth cohort levels (see Bertrand, Duflo,
and Mullainathan (2004), Donald and Lang (2007), and Moulton (1986)); the in-
dividual age-specific vaccination decision in the same state tends to be correlated
because individuals in the same state are exposed to the same policy environment,
e.g., federal-state (vaccination) policies and education system.
Within the clustered data, the assumption for the error term is E[vist
v
jst|X] =
ρσ2 > 0 for individual i and j in the same state, s, and the same year of birth,
t, where ρ is the intraclass correlation coefficient (ICC) and σ2 is the residual
variance (see Angrist and Pischke (2009, 231f)). There is no standard ICC method
for binary outcome variables41, but within regression frameworks, the influence of
ICC depends on the level of clustering. Additionally, the regression model 3
with state-fixed effects allows state-specific intercepts that account for within-
group error correlation next to cluster robust standard errors (so-called ‘cluster-
specific effects models’ in Cameron and Miller (2016, p. 8)). Thus, clustering
and cluster fixed effects are common practice (see Cameron, Gelbach, and Miller
(2011, p. 242)).
The other challenge in DD models is policy autocorrelation inducing a serial
correlation problem. For example, the persistence of regional structural factors or
a regional shock could induce time-series correlation at the state level. A practical
solution suggested by Bertrand, Duflo, and Mullainathan (2004, p. 267) is to col-
lapse data into a pre-period and post-period. This is mentioned in the regression
equation 2. Additionally, here, another quick fix is to go to the next higher clus-
tering level (states) for the calculation of the standard errors and to allow residual
correlation over time within states (see Angrist and Pischke (2009, p. 319)). How-
39Normally, in ordinary-least-square regressions, standard errors are underestimated (over-
states t-statistics) if the data are clustered (see Cameron and Miller (2016)).
40The KiGGS study design is a two-stage cluster sampling scheme (nested clusters). The
first stage includes 167 study locations over all states; at the second stage, a random sample
from the population register is drawn (see Kamtsiuris, Lange, and Rosario (2007)).
41Wu, Crespi, and Wong (2012) compared five ICC estimation procedures for binary data
and discussed the shortcomings.
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ever, this approach has its price42 in a reduction of clusters: with higher cluster
aggregation and smaller group number, a common and simple correction43 for the
inference is to use a T (G-1) distribution for p-values and critical values instead
of the standard normal distribution (see Cameron and Miller (2016, p. 11)). In
Section 7.1, I will review the robustness of the results depending on the chosen
level of aggregation over the DD regression models.
6 Results
6.1 Age shift
The linear predictions by measles vaccination, age group and groups are pre-
sented in Table 2.4. For the first dose, both treatment and control group reach
approximately 90 % for children aged under 3 years. Within treated states, the
probability for the second dose is approximately 70 % for both age groups, 2 to 4
years and 5 to 6 years. Within in the younger age group, the probability is over 5
times larger and approximately 15 percentage points higher for the older children
compared to those in the control group. The control group had a probability of
10 (49) % for age group 2 to 4 years (5 to 6). In the older age group, there are
only significant differences in 2005.
For visualization of the three-way interaction regression results, I plot age- and
group-specific marginal effects over periods. The left graph in Figure 3 plots the
predicted vaccination probability over the three survey periods: the average rate
of all 2- to 6-year-old children increases from below 60 % in 2003 to 70 % in 2004
and 75 % in 2005 in the treatment group and no time effects within the control
group. Looking at the age-specific rates by survey periods in the middle and right
graphs, this upwards shift holds for both age groups in the treatment group. For
the control group, predicted probabilities stay constant over time, with a higher
level in the older age group.
42With clustering on the highest possible aggregation level, the state level here, the number of
clusters is 16, raising the question of whether the standard errors are also calculated incorrectly.
For Germany, there is research using similar evaluation frameworks for policy analyses on state-
level variation, e.g., to analyze bans (see Anger, Kvasnicka, and Siedler (2011) and Marcus and
Siedler (2015)) or schooling duration (Pischke (2007)). An unfinished discussion exists about
the minimum number of clusters and some ‘solution’ procedures (see Angrist and Pischke (2009,
231f), Hansen (2007a,b)). One example is a bias correction with the bias-reduced linearization
procedure by Bell and McCaffrey, but it does not work in a DD model (Angrist and Pischke
(2009, p. 239)).
43Stata takes into account the number of clusters and chooses the distribution for critical
values.
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Table 2.4: Predicted vaccination probability by dose, group and age
Measles Age- TG CG
dose group Margin [95% CI ] Margin [95% CI ]
Pr(1 x m.d. = 1) 1 – 2 0.898 0.866 0.930 0.890 0.847 0.934
Pr(2 x m.d. = 1)
2 – 4 0.676 0.647 0.704 0.102 0.077 0.128
5 – 6 0.735 0.703 0.768 0.487 0.400 0.573
Notes: Average predicted probabilities calculated as the average of the probability
among individuals in the LPM with state x year of birth clustered S.E. using Stata’s
.margins.
Aside from the positive significant development within the treated states, one
should note that the necessary herd immunity threshold of 95 % is still missed by
20 percentage points within this age group.
Figure 3: 2nd measles vaccination by agegroups and period
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Source: KiGGS data, own calculations.
Assuming age squared and supplementary estimating a probit model, the re-
sults remain similar, and Figure 7 and 8 in the Appendix show the same pattern:
the predicted probabilities are constant in the treatment group and increase in the
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control group with age (on the left). Over time, the probabilities increase for the
treatment group for age 3 to approximately 5 but remain constant for the control
group (on the right).
Additionally, the results raise the question as to whether this development
directly causes the 2001 adaption, and if so, how strongly. For an age-specific
causal interpretation of the policy effects, information on the second measles dose
is required for the same age groups for the policy, but is not available. Therefore,
a causal analysis for the direct policy effect is possible for children aged 7 years
and older before and after the adaption. Fortunately, the indirect policy effect
could be explored in this manner as well.
6.2 Policy evaluation
Figure 4 shows the means of vaccination rates by birth cohorts and groups for
both measles vaccinations based on children with vaccination cards. The vertical
black line is the 2001 recommendation adaption at the first affected birth cohorts
and separates pre-period and post-period; the 2000 birth cohort was the first for
which the primary vaccination should be finished at age 2, the 1996 birth cohort
was the first for which school entry health exam and 7th birthday were after the
2001 adaption.
The DD regression results with one collapsed pre-cohorts and post-cohorts44
(indicator variable POST for post-cohorts) for both the first measles dose at
age 2 and the second at age 7 are presented in Table 2.5. Column M 1 is the
DD model without additional explanatory variables. In specification M 2 the
parental, household and child controls are included. In M 3 state fixed effects allow
state-specific intercepts to account for differences in levels and for intracluster
correlations.
The temporal development in the vaccination probability (coefficient for POST
in M 3) shows no change over time for the first measles dose and an increase of
over 13 percentage points for the second dose, which implies a rather large secular
trend.
The same for the average outcome levels in both groups in the pre-period that
is estimated by the TG indicator: After including controls, there is no difference
between control and treatment group for the first dose but a significant level dif-
ference of 7.5 percentage points in favor of the control group (M 2). Specification
44See Section 4.2 for period classification.
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M 3 allows state-specific intercepts to account for possible within-group correla-
tion, but they are not suitable for interpretation at the state level, as there are,
for example, a number of small states.
Figure 4: 2nd measles vaccination by age and period
0
20
40
60
80
100
 
19
96
19
97
19
98
19
99
20
00
20
01
20
02
20
03
 
1st measles dose at age 2
 
 
 
 
 
 
 
19
93
19
94
19
95
19
96
19
97
19
98
 
HIT
CG
TG
2nd measles dose at age 7
M
ea
n 
va
cc
.c
ov
er
ag
e 
(in
 %
)
Birth cohorts
Notes: KiGGS data, own calculations. The 2001 adaption is indicated by the
vertical line (black).
The parameters of interest, the DD coefficients (TG x POST), indicate the
adaption policy effects: for both the first and second measles dose, the adaption
increases the likelihood of a timely vaccination status by over 9 percentage points
significantly at the 1% and 5% significance levels.45 The average vaccination rate
in the pre-period was 83.9 % (74.5 %) for the first measles dose and 60.4 % (48.4
%) for the second dose in the treatment (control) group. If one then sets the DD
coefficients in relation to the counterfactual conditional in order to calculate the
effect size, the result for the first vaccination is an increase of 12.2 % and for the
second vaccination of 12.6 %.46
45The results of nonlinear probit estimations for M 2 are similar, calculating margins and the
effect of interest as differences of cross differences (see Table 2.17 in the Appendix).
46first m.d.: 9.883.9−3.6 ; second m.d.:
9.3
60.4−13.3 .
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Taking into account the level difference in the previous period, this means a
higher timely vaccination probability for the first vaccination in the treatment
group after adaption and a resolution to the level of the control group, which
itself experienced a significant increase in this time.
Table 2.5: Pre-post estimates - 1st and 2nd measles dose
Dep. var.: child’s vaccination status
Pr(1st measles dose at age 2 = 1)
M 1 M 2 M 3
POST -0.019 (0.023) -0.038 (0.025) -0.036 (0.025)
TG -0.098∗∗∗(0.021) -0.027 (0.022)
TG x POST 0.119∗∗∗(0.028) 0.097∗∗∗(0.029) 0.098∗∗∗(0.027)
N(df) 3,075 (3,072) 3,075 (3,018) 3,075 (3,004)
adj. R2 0.013 0.237 0.237
Pr(2nd measles dose at age 7 = 1)
M 1 M 2 M 3
POST 0.176∗∗∗(0.031) 0.127∗∗∗(0.035) 0.133∗∗∗(0.038)
TG -0.119∗∗∗(0.023) -0.075∗∗∗(0.025)
TG x POST 0.073 (0.045) 0.098∗∗ (0.044) 0.093∗∗ (0.044)
N(df) 2,459 (2,456) 2,459 (2,397) 2,459 (2,383)
adj. R2 0.064 0.196 0.202
Controls
√ √
State FE
√
Notes: LPM with clustered standard errors (in parentheses) at
the state x year of birth level. Significance: *p<0.1, **p<0.05,
***p<0.01. Controls are control variables child (gender, medical vac-
cination advice, reasons against vaccination, chronic diseases, well-
child visits, child care and/or school entry, timely vaccination record
of hepatitis B/first measles), and control variables household (income,
ISCED-97, parental occupation, migration background, no. of chil-
dren in household, firstborn indicator, local living area).
Next, the DD framework is stratified with two treatment regions: to consider
the different immunization policies until reunification all ‘old’ (West Germany)
and all ‘new’ federal states except the control group (East Germany) are grouped
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together. Despite the policy history, both groups respond similarly to the adapta-
tion: For both measles doses, the point estimate is greater in the old states. For
the second dose, the DD point estimate of the East states is 6 percentage points,
but not significantly different from the massive and significant time effect of the
control group (0.133). The results are shown in Table 2.6 column East and West.
Table 2.6: Pre-post estimates - east/west
Dep. var.: child’s vaccination status
Pr(1st measles dose at age 2 = 1)
All East West
POST -0.036 (0.025) -0.036 (0.025)
TG x POST 0.098∗∗∗(0.027) 0.085∗∗∗(0.030) 0.103∗∗∗(0.028)
adj. R2 0.234 0.237
Pr(2nd measles dose at age 7 = 1)
All East West
POST 0.133∗∗∗(0.038) 0.133∗∗∗(0.038)
TG x POST 0.093∗∗ (0.044) 0.060 (0.054) 0.104∗∗ (0.046)
adj. R2 0.157 0.202
Notes: LPM with clustered standard errors (in parentheses) at the state
x year of birth level. Significance: *p<0.1, **p<0.05, ***p<0.01. All
specifications include state FE and control variables child (gender, med-
ical vaccination advice, reasons against vaccination, chronic diseases,
well-child visits, child care and/or school entry, timely vaccination record
of hepatitis B/first measles), and control variables household (income,
ISCED-97, parental occupation, migration background, no. of children
in household, firstborn indicator, local living area).
As the adaption is shown to have positive significant effects on both vacci-
nation decisions, possible short-term dynamic effects within the post-period are
considered below.
In Table 2.7, the last column are the results of the dynamic DD regression with
several cohorts before and after policy adaption to analyse (short-term) dynamic
policy patterns. The middle column contains the previous results for comparison.
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Table 2.7: Pre-post estimates - policy dynamics
Dep. var.: child’s vaccination status
Pr(1st measles dose at age 2 = 1)
TG x POST 0.098∗∗∗(0.027)
TG x 1996 (pre) 0.017 (0.019)
TG x 1997 (pre) 0.034 (0.023)
TG x 1998 (pre) reference group
TG x 2001 (post) 0.120∗∗∗(0.016)
TG x 2002 (post) 0.103∗∗∗(0.023)
TG x 2003 (post) 0.114∗∗∗(0.025)
adj. R2 0.237 0.238
Common trend F (2, 93) =
F (n,m)(Prob > chi2) 1.21 (0.3031)
Pr(2nd measles dose at age 7 = 1)
TG x POST 0.093∗∗ (0.044)
TG x 1993 (pre) 0.022 (0.027)
TG x 1994 (pre) reference group
TG x 1996 (post) 0.098∗∗∗(0.027)
TG x 1997 (post) 0.084∗∗∗(0.028)
TG x 1998 (post) 0.147∗∗∗(0.037)
adj. R2 0.207 0.252
Common trend F (1, 78) =
F (n,m)(Prob > chi2) 0.72 (0.3992)
Notes: LPM with clustered standard errors (in parentheses) at the state
x year of birth level. Significance: *p<0.1, **p<0.05, ***p<0.01. All
specifications include state FE and control variables child (gender, med-
ical vaccination advice, reasons against vaccination, chronic diseases,
well-child visits, child care and/or school entry, timely vaccination record
of hepatitis B/first measles), and control variables household (income,
ISCED-97, parental occupation, migration background, no. of children
in household, firstborn indicator, local living area).
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First, looking at the significance of the pre-policy interaction terms, the com-
mon trend assumption for the first measles dose (the years 1996 and 1997 (TG x
1996 and TG x 1997) compared to 1998, the last-pretreatment period (reference
group)) and the second (TG x 1993 compared to reference group 1994) holds: the
null hypothesis that the temporal development between the control and treatment
groups is equal before the policy introduction could not be rejected.
Looking at the dynamics of policy, for all post-cohorts affected by the adaption,
the vaccination probability increases significantly: the first dose point estimates
of the post-policy period appear to be constant for the birth cohorts 2001 to 2003
(TG x 2001=.12 to TG x 2003=.114) and increasing, but are not statistically
different, for the cohorts 1996 to 1998 (TG x 1996=.098 to TG x 1998=.147).
Comparing these results for the second dose with the group differences of
the age shift in Section 6.1 the effects here are clearly smaller, but causal. As
previously described within the DD analyses, older cohorts had to be included,
and for that, the recommendation adaptation replaces the upcoming previous
vaccination recommendation: when the adaption came into force in 2001, the
post-period cohorts (1996 to 1998) were already 3 years and older, and for them,
the vaccination for the second dose was immediately due. Additionally, the pre-
policy practice in both groups is fully considered to control the vaccination status
in the context of the School Medical Entry and, if necessary, to initiate vaccination.
7 Robustness
In this section, I address concerns regarding my empirical strategy as mentioned
before. First, the clustering level will be changed, allowing different error rela-
tionships within the chosen units and calculating the corresponding standard er-
rors. Second, instead of birth cohorts, I use school cohorts for the second measles
dose, because the school entry health exam is appointed in the preschool year
for the forthcoming school beginners. Third, the parental vaccination decision for
measles might be influenced by other contemporaneous vaccination decisions (here
rubella and mumps). Therefore, I estimate a three-equation model as seemingly
unrelated. Fourth, I check for parallel events that possibly influence vaccination
demand. Finally, I perform a placebo test on a preventive health examination.
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7.1 Clustering within DD
Avoiding potential biases in the estimation of the standard errors (see the discus-
sion in Section 5.3), it is important to account for the possible correlation of the
errors ist across time and/or space.
Checking the robustness of the main results, I apply different clustering levels.
I allow for any covariance structure within regional areas over time by computing
the standard errors clustered at the federal state (policy aggregation level) and
the sample points (sampling structure) level. Additionally, I compute standard
errors clustered at the state-time level with only two cohort periods (pre-post)
and compare these standard errors with the chosen level in the main specification,
the state and year of birth level. Finally, robust and OLS standard errors are
calculated. Shown in Table 2.8 are the standard errors at the different clustering
levels.
In the upper panel in Table 2.8, the policy effect for the first measles dose
appears robust over all specifications. For the second dose, the standard errors
are increasing with lower aggregation assumption for the clustering.
Table 2.8: Pre-post estimates - clustering
Dep. var.: child’s vaccination status
Coef. Pr(1st measles dose at age 2 = 1)
TG x POST 0.098 ∗∗∗(0.014) ∗∗∗(0.010) ∗∗∗(0.027) ∗∗∗(0.038) ∗∗(0.042)
No. of clusters 16 32 94
Pr(2nd measles dose at age 7 = 1)
TG x POST 0.093 ∗∗∗(0.019) ∗∗∗(0.014) ∗∗ (0.044) ∗ (0.056) ∗ (0.056)
No. of clusters 16 32 79
Cluster-standard state state x state x robust1 OLS
errors at level pre-post year of birth
Notes: LPM with level-clustered standard errors are in parentheses. 1 White het-
eroskedastic. Significance: *p<0.1, **p<0.05, ***p<0.01. All specifications include
state FE and control variables child (gender, medical vaccination advice, reasons
against vaccination, chronic diseases, well-child visits, child care and/or school en-
try, timely vaccination record of hepatitis B/ first measles), and control variables
household (income, ISCED-97, parental occupation, migration background, no. of
children in household, firstborn indicator, local living area).
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7.2 School cohorts
The STIKO recommendations for the second measles dose suggested School Med-
ical Entry in the preschool year as the practical point in time to control the
up-to-date vaccination status. One might consider school cohorts as the affected
policy cohort. Next to public health policy, education and school policy is ad-
ministered by the federal states. Therefore, school cohorts differ slightly between
states because the school age cut-off47 is different within a three month span:
There are eight states with a cut-off at June 30, two states with an August 30
cut-off and six with a September 30 cut-off. These dates were considered in the
analysis.
Table 2.9: Pre-post estimates - cohorts
Dep. var.: child’s vaccination status
Pr(2nd measles dose at age 7 = 1)
Birth cohorts (N=2,459) School cohorts(N=2,669)
TG x POST 0.093∗∗ (0.044) TG x POST 0.113∗∗ (0.051)
adj. R2 0.212 adj. R2 0.183
TG x 1993 (pre) 0.022 (0.027) TG x 1993/94 (pre) -0.032 (0.020)
TG x 1994 (pre) reference group TG x 1994/95 (pre) reference group
TG x 1996 (post) 0.098∗∗∗(0.027) TG x 1995/96 (post) 0.068∗∗ (0.028)
TG x 1997 (post) 0.084∗∗∗(0.028) TG x 1996/97 (post) 0.085∗∗∗(0.026)
TG x 1998 (post) 0.147∗∗∗(0.037) TG x 1997/98 (post) 0.228∗∗∗(0.026)
adj. R2 0.252 adj. R2 0.199
Common trend F (1, 78) =
F (n,m)(Prob > chi2) 2.51 (0.1175)
Notes: LPM with clustered standard errors (in parentheses) at the state x year of
birth and at state x school cohort level. Significance: *p<0.1, **p<0.05, ***p<0.01.
All specifications include state FE and control variables child (gender, medical vac-
cination advice, reasons against vaccination, chronic diseases, well-child visits, child
care and/or school entry, timely vaccination record of hepatitis B/first measles),
and control variables household (income, ISCED-97, parental occupation, migration
background, no. of children in household, firstborn indicator, local living area).
The policy adaption in 2001 was released in July next to the start of school,
so the 2002/2003 school cohort, born in the second half of 1995 and the first half
of 1996, was the first cohort that was affected by the adaption.
47The child starts school in the year in which his or her 6th birthday is before the cut-off.
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The results for the school cohorts are robust with the standard and the dy-
namic policy model; with school cohorts, the increasing dynamics are slightly
steeper.
7.3 MMR - seemingly unrelated
Since the mid-1980s, the trivalent combination vaccine measles-mumps-rubella
has been initially recommended for simultaneous vaccinations in addition to the
existing monovalent vaccines. Therefore, the measles vaccination can also be
viewed as a conditional, non-independent decision with the other two vaccinations.
The seemingly unrelated regression (SUR) model48:
Pr(V ACvisτ = 1|.) = γs + λτ + βDsτ +Xisτδ + vist
with V ACvisτ is an indicator for whether individual i living in state s in cohort
τ has been vaccinated against v = 1, .., V with V = 3 for set (measles, mumps,
rubella)
Table 2.10: Pre-post estimates - seemingly unrelated
Dep. var.: child’s vaccination status
Pr(2nd ... dose at age 7 = 1)
measles mumps rubella
POST 0.122∗∗∗(0.037) 0.120∗∗∗(0.037) 0.114∗∗∗(0.035)
TG -0.073∗∗∗(0.025) -0.075∗∗∗(0.025) -0.081∗∗∗(0.025)
TG x POST 0.101∗∗ (0.044) 0.101∗∗ (0.044) 0.101∗∗ (0.044)
N 2,459
Notes: LPM with clustered standard errors (in parentheses) at
the state x year of birth level. Significance: *p<0.1, **p<0.05,
***p<0.01. Controls are control variables child (gender, medical vac-
cination advice, reasons against vaccination, chronic diseases, well-
child visits, child care and/or school entry, timely vaccination record
of corresponding first dose), and control variables household (income,
ISCED-97, parental occupation, migration background, no. of chil-
dren in household, firstborn indicator, local living area).
48I used Roodman’s Stata .cmp that allows for clustering (see Roodman (2009)).
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The results highlight a similar pattern for all three vaccinations: starting from
a higher level in the control group, an increase over time for both the control and
treatment groups could be observed with an additional policy effect of approxi-
mately 12 to 13 percentage points for all vaccinations.
7.4 Outbreak or policy?
The causal inference within DD regression frameworks persists on the common
trend assumption and that there are no other secular trends or events influenc-
ing the vaccination decision. Regional outbreaks could be such events. There-
fore, I divide the treatment states into two groups, one with a documented
measles outbreak in the post-policy period and the other with no such event.
Database are publications of the European Centre for Disease Control and Preven-
tion (ECDC) describing regional outbreaks (see Hellenbrand et al. (2003), Siedler
(2005), Siedler, Hellenbrand, and Rasch (2002), and Siedler et al. (2006)): For the
period 2001 to 2005, there were outbreaks in regions of Bavaria (November 2001
and March-July 2005), Lower Saxony (November 2001-March 2002), North Rhine
Westphalia (January-March 2002), Hesse (January-May 2005), and Schleswig-
Holstein (January-April 2001). Measles outbreaks and their reports are usually
restricted on local areas, e.g., counties. However, there is no local information in
the KiGGS data within the states. Therefore, the separation can be made only
very roughly at the level of the federal states.
Table 2.11 shows the results for both measles vaccinations: For the first and
the second measles dose, there is no difference between the two groups.
Outbreaks may affect demand, but the question is whether this occurrence is
only regional. The reporting of measles epidemics is often very medial, so it is not
limited to local print media in Germany, especially in the considered time period.
Furthermore, measles outbreaks are not uncommon, since due to their infection
potential at low vaccination rates, outbreaks occur regularly and reoccur partly
regionally.
In Section 8, I will take a closer look at incidences in the period after policy
adaption.
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Table 2.11: Pre-post estimates - outbreaks
Dep. var.: child’s vaccination status
Pr(1st measles dose at age 2 = 1)
All Outbreaks1 No outbreaks
TG x 2001 (post) 0.120∗∗∗(0.016) 0.156∗∗∗(0.017) 0.092∗∗∗(0.024)
TG x 2002 (post) 0.103∗∗∗(0.023) 0.094∗∗∗(0.032) 0.108∗∗∗(0.030)
TG x 2003 (post) 0.114∗∗∗(0.025) 0.101∗∗∗(0.022) 0.125∗∗∗(0.038)
adj. R2 0.235 0.238
N 3,075 3,075
Common trend F (2, 93) = F (2, 93) =
F (n,m)(Prob > chi2) 2.16 (0.1216) 0.10 (0.9070)
Pr(2nd measles dose at age 7 = 1)
All Outbreaks1 No outbreaks
TG x 1996 (post) 0.098∗∗∗(0.027) 0.133∗∗∗(0.057) 0.056∗ (0.032)
TG x 1997 (post) 0.084∗∗∗(0.028) 0.070∗ (0.054) 0.100∗∗∗(0.034)
TG x 1998 (post) 0.147∗∗∗(0.037) 0.157∗∗∗(0.056) 0.131∗∗∗(0.036)
adj. R2 0.167 0.208
N 2,459 2,459
Common trend F (1, 78) = F (1, 78) =
F (n,m)(Prob > chi2) 0.01 (0.9052) 2.30 (0.1335)
Notes: LPM with clustered standard errors (in parentheses) at the state x
year of birth level. Significance: *p<0.1, **p<0.05, ***p<0.01. 1 Bavaria,
Hesse, Lower Saxony, North Rhine Westphalia and Schleswig-Holstein. All
specifications include state FE and control variables child (gender, medical
vaccination advice, reasons against vaccination, chronic diseases, well-child
visits, child care and/or school entry, timely vaccination record of Hepatitis
B/first Measles), and control variables household (income, ISCED-97, parental
occupation, migration background, no. of children in household, firstborn
indicator, local living area).
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7.5 Placebo test
As a final robustness analysis and to assess whether my results might be driven
by a secular trend, I look at the adaption effects of a placebo health outcome.
The outcome variable of the policy adaption, the measles status of the child, is
replaced by another prevention measure that was not the content of the adaption
but is done in parallel. One possibility for this would be a child health screening
such as well-child visits. The U 9 scheduled for the age of 5 years (between the
60th and 64th month of life) or U 10 after the 7th birthday would be suitable.
After the U10, which has been offered in Germany since 2006, no information is
available on the birth cohorts used. In contrast to age-recommended vaccinations,
the execution of these examinations must take place within a certain time interval
and cannot be made up after being exceeded (see Gemeinsamer Bundesausschuss
(2017, p. 7)).
Table 2.12 presents the results of the placebo outcome regression. For this
child screening, there are no trend differences between the both groups in the
considered period of time either before timeliness adaptation in 2001 or in the
years thereafter. This and the previous outbreak analysis give no indication of a
parallel policy trend and support the previous causal analysis.
8 A look at incidence rates in the long-run
The long-term expectations of a vaccination policy are high immunization rates
and associated declining disease rates in the population. One goal of the timeliness
adaption for the second measles vaccination in the context of primary immuniza-
tion is to increase the protection of children under the age of 5 years.
Since 2001, it has been a legal obligation to report all notifiable disease cases
and pathogens to the RKI. In Figure 5, the incidence cases per million population
in Germany are plotted from 2001 to 2016.49 In addition, the proportion of
incidence cases that occurred in the age groups 0 to less than 5 years and 0 to less
than 15 years are calculated. In line with the policy change, the two groups from
the previous analyzes are again compared; the left figure shows the average over
all federal states without Saxony, and the right contains the Saxon measles cases.
First, it can be seen that there were still regular outbreaks during this period,
which occurred at a distance of 2 to 4 years (gray bars). It can also be stated that
in 7 of the 16 years, Saxony had an incidence rate of less than 1 case per million
49Data for measles incidences are available until 2018, but population statistics end in 2016.
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Table 2.12: Pre-post estimates - placebo
Dep. var.: Dep. var.:
child’s child’s
vaccination screening
status status
Pr(2nd m.d. at age 7 = 1) Pr(U 9 screening = 1)
TG x 1993 (pre) 0.022 (0.027) -0.022 (0.023)
TG x 1994 (pre) reference group reference group
TG x 1996 (post) 0.098∗∗∗(0.027) 0.026 (0.016)
TG x 1997 (post) 0.084∗∗∗(0.028) 0.010 (0.017)
TG x 1998 (post) 0.147∗∗∗(0.037) -0.001 (0.023)
adj. R2 0.167 0.065
N 2,459 2,459
Common trend F (1, 78) =
F (n,m)(Prob > chi2) 0.95 (0.3321)
Notes: LPM with clustered standard errors (in parentheses) at the state x year
of birth level. Significance: *p<0.1, **p<0.05, ***p<0.01. 1 Bavaria, Hesse,
Lower Saxony, North Rhine Westphalia and Schleswig-Holstein. All specifica-
tions include state FE and control variables child (gender, medical vaccination
advice, reasons against vaccination, chronic diseases, well-child visits, child care
and/or school entry, timely vaccination record of Hepatitis B/first Measles), and
control variables household (income, ISCED-97, parental occupation, migration
background, no. of children in household, firstborn indicator, local living area).
population and generally below-average incidence rates. In recent years, however,
the local rates in Saxony are increasing with an above-average high in 2016.
Second, in the states where the measles timeliness adaption was implemented
in 2001, there is a steady decline in the proportion of disease cases in both age
groups. For Saxony, in the years in which the incidence rate was over 5 cases per
million population, the proportion of cases among children under 15 years was
50 % or even higher.
The average German incidence rates, however, are regionally very different:
for instance, in Germany, the absolute incidences were over 1,500 cases50 in 2001,
2002, 2006, 2011, 2013, 2015, and 2017. For example, in North-Rhine Westphalia,
in 2 of these 7 years, the regional quota was over 50 % (53 in 2017; 74 in 2006),
and in 2 of these 7 years, the quota was over 25 % (26 in 2001; 34 in 2002).
50Relative to the German population, with approximately 82 million inhabitants, the cases
are over 18 per million population, which is half of the worldwide average in the year 2015 and
over 18 times above the measles eradication definition (see Section 1).
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Figure 5: Measles cases per million and proportions of age groups
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9 Conclusion
According to current recommendations, timely primary vaccination should be
completed for all children in the first two years of life. Almost all recommended
immunizations require a certain number of vaccinations to ensure the necessary
immune response.
The results here, representing further analyses of health department’s report-
ing data and claims data of health insurance, show a positive development of
vaccination status for Germany in the last 15 years. The introduction of the
adaption already shows initial success in the short and long run. Rieck et al.
(2013) analyzed claims data for the birth cohorts 2004 to 2006 regarding age and
vaccination status: their results show high first measles dose status and an in-
creasing second measles dose status for 2- and 3-year-old children, which are in
line with my findings. Compared to the rates at the school entry health exam,
the level of the first dose is reached already at a young age (see Figure 1). For
the second dose, the difference between the rates at 3 years and before school
entry differs between 10 and 15 percentage points when including the Free State
37
of Saxony in the data.
It can be assumed that the opportunity costs for measles vaccinations de-
creased by the 2001 adaption because the vaccinations take place next to the
well-child visits in the first years of life. Due to higher parental screening compli-
ance in the first years, doctor visits are increased, time costs are reduced, and the
probability of having already experienced an infection is lower under otherwise
identical conditions. These results give reason to certify a nonbinding vaccination
policy; however, the incentives should be used as best as possible, especially with
a recommendation policy framework.
From an economic point of view, it is of great benefit to know how the distribu-
tion of those policy effects is accomplished on both market sides, i.e., vaccination
demand by parents and doctoral supply efforts. This consideration is important
to transfer and implement policy adaption efficiently. Limited by the data, this
remains here an open question.
Despite these positive findings, the coverage rates are still not sufficient to pre-
vent outbreaks, and in 2019, we are still far from having the nationwide coverage
required to build adequate protection and advance the elimination of the measles
virus.
The main problem is that a relatively high immunization rate is needed in
the population and a pure recommendation vaccination policy reaches its limits.
Whether in the case of measles, such as France and Italy, Germany should finally
achieve a vaccination mandate or intervene in other ways remains an exciting
political discussion.
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10 Appendix
Figure 6: Measles status by year of school entry health exam
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Table 2.13: Explanation of variables
Dependent variables
1st m.d.b measles vaccination status:
1 = child got 1st measles vaccination timely; 0
= else
2nd m.d.b measles vaccination status:
1 = child got 2nd measles vaccination timely; 0
= else
U9b screening status:
1 = child got U9 well-child visit; 0 = else
Control variables
Child characteristics
Genderb 1 = child is female; 0 = else
Child care under age 2b 1 = child care in the first/second year of life; 0
= else
School enrollment (4 cat.) regular; delayed; earlier; not yet
Well-child visitb (U6 to U9) 1 = child visited the screening; 0 = else
Medical advice against vaccination
(4 cat.)
MMR or one single component; all; single vac-
cination; non
Chronic illness under 2b (N=14) 1 = child has illness within the first second years
of life; 0 = else
Chronic illness under 3b (N=14) 1 = child has illness within the first three years
of life; 0 = else
Reasons against vaccination (3 cat.) yes; no; don’t know
Vaccination side effects (3 cat.) yes; no; don’t know
Timely hepatitis B vaccinationb 1 = child got vaccination at age of 2; 0 = else
Parental and household characteristics
Professional qualification
(8 cat., mother and father)
apprenticeship; professional training school, vo-
cational college; specialist college; technical col-
lege, engineering college; university, polytech-
nic; other training qualification; No professional
qualification; still in professional training.
Education (3 cat.) max. household ISCED (1997): low, middle,
high
Income (4 cat.) 0 < 1,500; 1,500 < 2,250; 2,250 < 3,000; 3,000
and more
Migration background (3 cat.) both sides; one-sided; non
Children in household (4 cat.) single child; two; three; four and more
Birth orderb 1 = child is firstborn, 0 = else
Region (4 cat.) rural (<5’ inhabitants), small town (5’ < 20’),
middle town (20’ < 100’), urban (> 100’)
b binary
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Table 2.14: Descriptive statistics - part 1
full Treatment Control
sample group (TG) group (CG)
N 6,272 5,571 701
Dependent variables
1st measles dose1 0.94 0.93 0.95
2nd measles dose1 0.72 0.70 0.26
1st measles dose (< 2)2 0.77 0.76 0.82
2nd measles dose (< 7)2 0.62 0.61 0.69
U 92 0.64 0.64 0.65
Control variables
Female 0.49 0.49 0.52
Age 12.9 12.9 12.6
Child care under age 2 0.19 0.18 0.32
Timely hepatitis B vaccination2 0.59 0.57 0.74
School enrollment
Regular 0.44 0.44 0.43
Delayed 0.03 0.03 0.04
Earlier 0.03 0.03 0.01
Not yet 0.50 0.50 0.51
Well-child visit
U6 0.96 0.96 0.98
U7 0.94 0.94 0.95
U8 0.73 0.73 0.73
Medical advice against vaccination
MMR or one component 0.01 0.01 0.00
All 0.00 0.00 0.00
Single vaccinations 0.03 0.04 0.00
Non 0.95 0.95 0.98
Parental reasons against vaccination
Yes 0.09 0.09 0.05
No 0.91 0.91 0.95
Don’t know 0.00 0.00 0.00
Vaccination side effects
Yes 0.02 0.02 0.02
No 0.98 0.98 0.98
Don’t know 0.00 0.00 0.00
Notes: 1 Mean values refer to cohorts of the up-to-date sample, 2 Mean
values refer to cohorts of the pre-post sample.
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Table 2.15: Descriptive statistics - part 2
full Treatment Control
sample group (TG) group (CG)
N 6,272 5,571 701
Professional qualification (mother/ father)
Apprenticeship 0.43/0.42 0.44/0.41 0.40/0.47
Professional training school 0.16/0.11 0.16/0.11 0.17/0.17
Vocational college 0.12/0.15 0.12/0.15 0.16/0.11
Engineering college/ applied university 0.06/0.09 0.06/0.09 0.09/0.08
University 0.11/0.15 0.11/0.16 0.14/0.14
Other training qualification 0.03/0.02 0.03/0.03 0.01/0.01
No professional training 0.08/0.05 0.08/0.05 0.01/0.01
Still in professional training 0.01/0.00 0.01/0.00 0.01/0.00
Household ISCED education
low 0.03 0.03 0.01
middle 0.48 0.48 0.50
high 0.49 0.49 0.49
Household income
0 < 1,500 0.17 0.16 0.21
1,500 < 2,250 0.27 0.26 0.36
2,250 < 3,000 0.30 0.30 0.25
3,000 and more 0.27 0.28 0.18
Migration background
both sides 0.09 0.10 0.01
one-sided 0.08 0.08 0.02
non 0.83 0.81 0.97
Children in household
Single child 0.18 0.17 0.22
Two 0.52 0.53 0.47
Three 0.20 0.20 0.20
Four and more 0.10 0.09 0.11
Firstborn 0.47 0.47 0.47
Region
Rural 0.26 0.25 0.38
Small town 0.27 0.26 0.31
Middle town 0.25 0.26 0.15
Urban 0.22 0.23 0.17
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Table 2.16: Descriptive statistics - part 3
full Treatment Control
sample group (TG) group (CG)
N 6,272 5,571 701
Chronic disease under 3 years
Allergic rhinitis/ conjunctivitis 0.01 0.01 0.01
Atopic dermatitis/ eczema 0.12 0.12 0.12
Asthma 0.01 0.01 0.01
Chronic obstructive pulmonary disease 0.10 0.11 0.07
Pneumonia 0.06 0.06 0.04
Otitis media 0.33 0.33 0.32
Heart disease 0.02 0.02 0.02
Anemia 0.01 0.01 0.01
Epileptic seizure 0.03 0.03 0.03
Thyroid 0.00 0.00 0.00
Diabetes mellitus 0.00 0.00 0.00
Scoliosis 0.00 0.00 0.00
Migraine 0.00 0.00 0.00
Other diseases 0.13 0.13 0.16
Chronic disease under 2 years
Allergic rhinitis/ conjunctivitis 0.01 0.01 0.00
Atopic dermatitis/ eczema 0.10 0.10 0.09
Asthma 0.01 0.01 0.01
Chronic obstructive pulmonary disease 0.08 0.08 0.06
Pneumonia 0.04 0.05 0.04
Otitis media 0.22 0.22 0.21
Heart disease 0.02 0.02 0.01
Anemia 0.01 0.01 0.01
Epileptic seizure 0.02 0.02 0.02
Thyroid 0.00 0.00 0.00
Diabetes mellitus 0.00 0.00 0.00
Scoliosis 0.00 0.00 0.00
Migraine 0.00 0.00 0.00
Other diseases 0.09 0.09 0.11
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Figure 7: 2nd measles vaccination by age and period
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Source: KiGGS data, own calculations.
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Figure 8: 2nd measles vaccination by age and period - probit
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Source: KiGGS data, own calculations.
Table 2.17: Predicted vaccination probability by group and time - probit
Pr(1 x m.d. = 1) Pr(2 x m.d. = 1)
Margin [95% CI ] Margin [95% CI ]
Pre # CG 0.798 0.762 0.834 0.559 0.532 0.586
Pre # TG 0.769 0.750 0.789 0.491 0.457 0.525
Post # CG 0.754 0.710 0.798 0.720 0.653 0.787
Post # TG 0.832 0.812 0.851 0.742 0.703 0.781
H0 : Pre # CG=Pre # TG 0.1850 0.0002
H0 : Pre # CG=Post # CG 0.1131 0.0002
H0 : Pre # TG=Post # TG 0.0000 0.0000
H0 : Post # CG=Post # TG 0.0009 0.5853
Contrast [95% CI ] Contrast [95% CI ]
TIME#TG 0.107*** 0.048 0.167 0.091** 0.0017 0.179
Notes: Average predicted margins calculated among group and time using Stata’s
.margins with contrast option for the difference of cross-differences.
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